(195 days)
No
The summary describes a hemodynamic monitoring and data management system with standard vital sign acquisition and processing, but there is no mention of AI or ML capabilities.
No.
The device is intended for monitoring, data acquisition, processing, and management of physiological and hemodynamic data, not for providing therapy.
Yes
The device's intended use explicitly states "complete physiological/hemodynamic monitoring," "clinical data acquisition," and "medical image and data processing," which are activities integral to diagnosis. It also mentions "analytical assessment" and the acquisition of data from other physiological monitoring systems, all of which contribute to understanding a patient's condition for diagnostic purposes.
No
The device description explicitly states that the system incorporates hardware components, including a Clinical Unit with a 'Front-End' unit that incorporates the Schiller Argus PB device (K012226), which is a vital signs monitoring device. It also mentions a control and documentation unit (Information System). While software is a key part of the system for data processing and management, it is not solely software.
Based on the provided information, the McKesson Cardiology™ Hemo device is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use focuses on physiological/hemodynamic monitoring, clinical data acquisition, processing, and management. It deals with data acquired directly from the patient's body (ECG, blood pressure, SpO2, temperature, CO2, cardiac output) and managing procedural information.
- Device Description: The device description confirms it's a hemodynamic monitoring system that acquires vital signs and other clinical data directly from the patient. It incorporates a vital signs monitoring device (ARGUS PB) which is also not an IVD.
- Lack of In Vitro Testing: There is no mention of the device being used to test samples taken from the body (like blood, urine, tissue) in a laboratory setting. IVD devices are specifically designed for testing these types of samples to provide information about a patient's health.
The McKesson Cardiology™ Hemo is a medical device used for in vivo monitoring and data management, not in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
McKesson Cardiology™ Hemo is intended for complete physiological/hemodynamic monitoring. clinical data acquisition, medical image and data processing, and analytical assessment.
McKesson Cardiology™ Hemo is also intended for patient/procedural data management, such as documentation, logging, reporting, storing, storing, carrying, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or sent to other devices, such as physiological monitoring systems, information management systems, image acquisition/storage devices, and other medical devices.
McKesson Cardiology™ Hemo is intended for use in the areas of: cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology, and other areas where patient/procedural data management is needed.
Use of the system is not intended for unattended patient monitoring or in situations where arrhythmia detection is required.
Product codes (comma separated list FDA assigned to the subject device)
MWI, DQK
Device Description
The McKesson Cardiology™ Hemo device is a hemodynamic monitoring system for monitoring vital signs, performing measurements and calculations, documenting procedure and patient data and interfacing to other systems and devices during and after procedures in the areas of in the areas of: cardiology, cardiac catheterization, electrophysiology, invasive radiology, and other areas where patient/procedural data management is needed.
McKesson Cardiology™ Hemo also acquires patient information from other hospital information systems and makes hemodynamic information available to them. It facilitates seamless interfacing with hospital information systems and cardiac image management, archiving and reporting systems.
McKesson Cardiology™ Hemo incorporates the FDA cleared the ARGUS PB vital signs monitoring device (K012226), manufactured by Schiller AG, which provides patient monitoring via:
- ECG leads .
- Invasive Blood Pressure (non-McKesson transducers) .
- SpO2 sensor .
- Non-invasive blood pressure (NIBP) cuff .
- . Temperature probe
- . Thermal Dilution Cardiac output temperature probe (connected to a non-McKesson Cardiac Output catheter)
- . CO2 (connected to non-McKesson cannulas or intubation tubes)
Disposables and accessories (transducers, cannulas and intubation devices) are not part of the McKesson Cardiology™ Hemo system, but are supplied by the end user facility as required.
McKesson Cardiology™ Hemo is composed of:
- A control and documentation unit (Information System) that is used for administration, . performing measurements, recording full disclosure, taking samples and entering procedure notes and overall data input and management of the patient and procedure data.
- A Clinical Unit that incorporates the 'Clinical System' and the 'Front-End' unit (which . incorporates the Schiller Argus PB device - K012226). The clinical unit is responsible for acquiring, analyzing and displaying patient vitals and other pertinent clinical data. The data is displayed on monitors.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and validation testing was performed on McKesson Cardiology™ Hemo to ensure it met all specifications. The device was further validated to ensure that it performs as intended. Performance testing was conducted to verify compliance with specified design requirements and relevant safety standards such as: IEC 60601-1, IEC 60601-2-49 and IEC 60601-1-8. In all instances, McKesson Cardiology™ Hemo functioned as intended and the observed results demonstrate substantial equivalence with the predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).
0
510(k) SUMMARY McKesson Israel Ltd.'s McKesson Cardiology™ Hemo
McKesson Israel Ltd. 4 HaNechoshet Street Tel Aviv lsrael 69710
| Contact Person: | Tomer Levy, VP Engineering |
|---|---|
| Phone: | +972 (0)3 7698000 |
| Facsimile: | +972 (0)3 6478593 |
DEC 0 5 2013
| Date Prepared: | April 28, 2013 |
|---|---|
| Name of the device | McKesson Cardiology™ Hemo |
| Common Name: | Cardiac monitor |
| Classification Name: | Monitor, Physiological, Patient, Without Arrhythmia Detection or Alarms |
| Classification Regulation | 21 CFR § 870.2300 |
| Classification Product code: | MWI |
| Subsequent Product code: | DQK |
| Device Class: | Class II |
| Predicate Device: | Medcon Ltd., Windsurfer (K050561), WITT BIOMEDICAL CORP Philips Xper Flex Cardio Physiomonitoring System/ Xper Information Management System (K101571) |
Intended Use / Indications for Use
McKesson Cardiology™ Hemo is intended for complete physiological/hemodynamic monitoring. clinical data acquisition, medical image and data processing, and analytical assessment.
McKesson Cardiology™ Hemo is also intended for patient/procedural data management, such as documentation, logging, reporting, storing, storing, carrying, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or sent to other devices, such as physiological monitoring systems, information management systems, image acquisition/storage devices, and other medical devices.
McKesson Cardiology™ Hemo is intended for use in the areas of: cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology, and other areas where patient/procedural data management is needed.
K131497 Page 1 of 3
1
User-adjustable alarms (both visual and audible) available in the system alert the operator to anomalous occurrences and facilitate timely responses.
Use of the system is not intended for unattended patient monitoring or in situations where arrhythmia detection is required.
Technological Characteristics
The McKesson Cardiology™ Hemo device is a hemodynamic monitoring system for monitoring vital signs, performing measurements and calculations, documenting procedure and patient data and interfacing to other systems and devices during and after procedures in the areas of in the areas of: cardiology, cardiac catheterization, electrophysiology, invasive radiology, and other areas where patient/procedural data management is needed.
McKesson Cardiology™ Hemo also acquires patient information from other hospital information systems and makes hemodynamic information available to them. It facilitates seamless interfacing with hospital information systems and cardiac image management, archiving and reporting systems.
McKesson Cardiology™ Hemo incorporates the FDA cleared the ARGUS PB vital signs monitoring device (K012226), manufactured by Schiller AG, which provides patient monitoring via:
- ECG leads .
- Invasive Blood Pressure (non-McKesson transducers) .
- SpO2 sensor .
- Non-invasive blood pressure (NIBP) cuff .
- . Temperature probe
- . Thermal Dilution Cardiac output temperature probe (connected to a non-McKesson Cardiac Output catheter)
- . CO2 (connected to non-McKesson cannulas or intubation tubes)
Disposables and accessories (transducers, cannulas and intubation devices) are not part of the McKesson Cardiology™ Hemo system, but are supplied by the end user facility as required.
McKesson Cardiology™ Hemo is composed of:
- A control and documentation unit (Information System) that is used for administration, . performing measurements, recording full disclosure, taking samples and entering procedure notes and overall data input and management of the patient and procedure data.
- A Clinical Unit that incorporates the 'Clinical System' and the 'Front-End' unit (which . incorporates the Schiller Argus PB device - K012226). The clinical unit is responsible for acquiring, analyzing and displaying patient vitals and other pertinent clinical data. The data is displayed on monitors.
2
McKesson Cardiology™ Hemo uses an intuitive interface that clearly displays patient data, procedure data, waveforms and numeric values. The performing physician views the monitor, and conveys instructions and procedure notes to the technician, who operates the application using a touch screen, keyboard and mouse.
Performance Data
Verification and validation testing was performed on McKesson Cardiology™ Hemo to ensure it met all specifications. The device was further validated to ensure that it performs as intended. Performance testing was conducted to verify compliance with specified design requirements and relevant safety standards such as: IEC 60601-1, IEC 60601-2-49 and IEC 60601-1-8. In all instances, McKesson Cardiology™ Hemo functioned as intended and the observed results demonstrate substantial equivalence with the predicate devices.
Substantial Equivalence
McKesson Cardiology™ Hemo is substantially equivalent to Medcon Ltd.'s Windsurfer (K050561), as well as Witt Biomedical Corp Philips Xper Flex Cardio Physiomonitoring System/ Xper Information Management System (K101571). McKesson Cardiology™ Hemo has the same intended use and similar indications, technological characteristics and principles of operation as the predicate devices.
The minor technological differences between McKesson Cardiology™ Hemo and its predicate devices raise no new issues of safety or effectiveness. Thus, McKesson Cardiology™ Hemo is substantially equivalent to previously- cleared predicate devices.
K131497 Page 3 of 3
62
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image contains the text 'Public Health Service'. The text is in a simple, sans-serif font and is horizontally aligned. The text appears to be part of a document or sign.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G619 Silver Spring, MD 20993-002
December 5, 2013
Mckesson Israel Ltd. Mr. Paul Sumner Director. Regulatory Affairs 5995 Windward Parkway Alpharetta, GA 30005 US
Re: K131497
Trade/Device Name: Mckesson Cardiology Hemo Regulation Number: 21 CFR 870.1025 Regulation Name: Monitoring, Physiological, Patient (Without Arrhythmia Detection Or Alarms) Regulatory Class: Class II Product Code: MWI, DQK Dated: October 22, 2013 Reccived: October 25. 2013
Dear Paul Sumner:
We have reviewed your Scetion 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and Please note: CDRH does not evaluate information related to contract liability adulteration. warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into cither class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Paul Sumner
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-638-2041 or (301) 796-7100 or at its Internet address number (800) free http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, piease note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Owen Paris -S
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indication for Use Statement
510(k) Number (if known):
Device Name: McKesson Cardiology™ Hemo
Indications for Use:
McKesson Cardiology™ Hemo is intended for complete physiological/hemodynamic monitoring. clinical data acquisition, medical image and data processing, and analytical assessment.
McKesson Cardiology™ Hemo is also intended for patient/procedural data management, such as documentation, logging, reporting, storing, storing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or sent to other devices, such as physiological monitoring systems, information managenient systems. image acquisition/storage devices, and other medical devices.
McKesson Cardiology™ Hemo is intended for use in the areas of: cardiology. cardiac catheterization. electrophysiology, radiology, invasive radiology, and other arcas where patient/procedural data management is needed.
User-adjustable alarms (both visual and audible) available in the system alert the operator to anomalous occurrences and facilitate timely responses.
Use of the system is not intended for unatiended patient monitoring or in situations where arrhythmia detection is required.
- AND/OR - Over-The-Counter
- AND/OR - (2) CFR 801 Subma Use Usc Prescription X (21 CFR 801 Subpart C) (Part 21 CFR 801 Subpart D) ・
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Digitally signed by
Owen P. Faris -S
Date: 2013.12.05
16:23:18-05'00'
McKESSON
Empowering Healthcare
K131497 Page 1 of 1
58